X-100406916-G-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_001184880.2(PCDH19):c.1682C>G(p.Pro561Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 23)
Consequence
PCDH19
NM_001184880.2 missense
NM_001184880.2 missense
Scores
13
3
1
Clinical Significance
Conservation
PhyloP100: 10.0
Genes affected
PCDH19 (HGNC:14270): (protocadherin 19) The protein encoded by this gene is a member of the delta-2 protocadherin subclass of the cadherin superfamily. The encoded protein is thought to be a calcium-dependent cell-adhesion protein that is primarily expressed in the brain. Mutations in this gene on human chromosome X are associated with sporadic infantile epileptic encephalopathy and to a female-restricted form of epilepsy (EFMR; also known as PCDH19RE). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.991
PP5
Variant X-100406916-G-C is Pathogenic according to our data. Variant chrX-100406916-G-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 206337.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-100406916-G-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCDH19 | NM_001184880.2 | c.1682C>G | p.Pro561Arg | missense_variant | 1/6 | ENST00000373034.8 | NP_001171809.1 | |
PCDH19 | NM_001105243.2 | c.1682C>G | p.Pro561Arg | missense_variant | 1/5 | NP_001098713.1 | ||
PCDH19 | NM_020766.3 | c.1682C>G | p.Pro561Arg | missense_variant | 1/5 | NP_065817.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCDH19 | ENST00000373034.8 | c.1682C>G | p.Pro561Arg | missense_variant | 1/6 | 1 | NM_001184880.2 | ENSP00000362125.4 | ||
PCDH19 | ENST00000255531.8 | c.1682C>G | p.Pro561Arg | missense_variant | 1/5 | 1 | ENSP00000255531.7 | |||
PCDH19 | ENST00000420881.6 | c.1682C>G | p.Pro561Arg | missense_variant | 1/5 | 1 | ENSP00000400327.2 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD3 genomes
Cov.:
23
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 23
GnomAD4 genome
Cov.:
23
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:4Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Developmental and epileptic encephalopathy, 9 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 15, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro561 amino acid residue in PCDH19. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 30287595). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PCDH19 protein function. ClinVar contains an entry for this variant (Variation ID: 206337). This missense change has been observed in individuals with clinical features of PCDH19-related conditions (PMID: 21053371, 28669061). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 561 of the PCDH19 protein (p.Pro561Arg). - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 06, 2021 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with X-linked developmental and epileptic encephalopathy 9 (MIM#300088). (I) 0110 - This gene is associated with X-linked disease. Heterozygous females and mosaic males are affected, however hemizygous males do not present with symptoms (PMID: 28669061). (I) 0200 - Variant is predicted to result in a missense amino acid change from proline to arginine. (I) 0254 - This variant is suspected mosaic. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools and highly conserved with a major amino acid change. (SP) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0703 - Other missense variants comparable to the one identified in this case have moderate previous evidence for pathogenicity. Alternative changes at the same residue, to alanine and serine, have previously been reported as pathogenic in individuals with X-linked developmental and epileptic encephalopathy 9 (MIM#300088) (ClinVar, PMID: 29866057). (SP) 0802 - This variant has moderate previous evidence of pathogenicity in unrelated individuals. The variant has previously been reported as pathogenic, in heterozygous females and a mosaic male, with X-linked developmental and epileptic encephalopathy 9 (MIM#300088) (ClinVar, PMID: 21053371, PMID: 28669061). (SP) 1102 - Strong phenotype match for this individual. (SP) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed) (by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
not provided Pathogenic:1Uncertain:1
Uncertain significance, flagged submission | clinical testing | Eurofins Ntd Llc (ga) | Oct 14, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 05, 2024 | Reported in two sisters with seizures and mild intellectual disability (PMID: 21053371); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27787195, 23708187, 32425876, 30287595, 34082468, 26986070, 29892053, 26659599, 22267240, 30582250, 28669061, 21053371) - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 17, 2016 | The p.P561R variant (also known as c.1682C>G), located in coding exon 1 of the PCDH19 gene, results from a C to G substitution at nucleotide position 1682. The proline at codon 561 is replaced by arginine, an amino acid with dissimilar properties. This alteration was detected with paternal transmission in two female siblings who both had intellectual disability, microcephaly, and developed various seizure types, including generalized tonic-clonic, absence, partial, and tonic, before age one (Depienne C et al. Hum. Mutat., 2011 Jan;32:E1959-75). This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6375 samples with coverage at this position. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
.;D;.
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;H;H
PrimateAI
Pathogenic
T
PROVEAN
Pathogenic
D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D
Sift4G
Pathogenic
D;D;D
Polyphen
1.0
.;D;D
Vest4
MutPred
Loss of glycosylation at T564 (P = 0.0425);Loss of glycosylation at T564 (P = 0.0425);Loss of glycosylation at T564 (P = 0.0425);
MVP
MPC
1.5
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at